Medicine and Dentistry
Diffuse Large B-Cell Lymphoma
100%
Large-Cell Lymphoma
73%
Diseases
60%
Rituximab
58%
Radiation Therapy
57%
Progression Free Survival
54%
Overall Survival
53%
Chimeric Antigen Receptor T-Cell Immunotherapy
50%
Axicabtagene Ciloleucel
46%
B-Cell Lymphoma
38%
Follicular Lymphoma
29%
Malignant Neoplasm
27%
Doxorubicin
25%
Non-Hodgkin Lymphoma
25%
Lenalidomide
22%
Chimeric Antigen Receptor T-Cell
21%
Cyclophosphamide
21%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
21%
MALT Lymphoma
21%
Vincristine
21%
Central Nervous System
20%
B Cell
19%
Ibrutinib
19%
Mantle Cell Lymphoma
19%
Adverse Event
19%
Arm
18%
Cytokine Release Syndrome
17%
Hodgkin's Lymphoma
17%
Clinical Trial
16%
Prednisone
16%
Survival Rate
14%
Autologous Stem Cell Transplantation
14%
Event Free Survival
13%
Hazard Ratio
13%
Infusion
13%
Chimeric Antigen Receptor
13%
T Cell
10%
Disease Exacerbation
10%
Etoposide
9%
Positron Emission Tomography-Computed Tomography
9%
Chemoimmunotherapy
9%
Aggressive Lymphoma
9%
Neoplasm
9%
International Prognostic Index
9%
Cytopenia
8%
Immunity
8%
Gene Expression Profiling
8%
Low Drug Dose
8%
Peripheral T-Cell Lymphoma
8%
Circulating Tumor DNA
8%
Keyphrases
Diffuse Large B-cell Lymphoma (DLBCL)
83%
Large B-cell Lymphoma
60%
Relapsed or Refractory
58%
Rituximab
47%
Chimeric Antigen Receptor T-cell Therapy
44%
Axicabtagene Ciloleucel
38%
Progression-free Survival
37%
Chimeric Antigen Receptor T Cells (CAR-T)
36%
Overall Survival
34%
Radiation Therapy
28%
Lymphoma Patients
27%
Complete Response
27%
Cyclophosphamide
26%
R-CHOP
25%
Follicular Lymphoma
25%
Doxorubicin
24%
Chemotherapy
23%
Lymphoma
22%
Standard of Care
22%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
21%
Mantle Cell Lymphoma
20%
Aggressive B-cell Lymphoma
18%
Prednisone
17%
Tisagenlecleucel
16%
Refractory Diffuse Large B-cell Lymphoma
16%
Phase II Study
14%
Ibrutinib
14%
Hodgkin Lymphoma
14%
Hazard Ratio
13%
Partial Response
13%
MD Anderson Cancer Center
13%
Confidence Interval
13%
B-cell Lymphoma
12%
Cytokine Release Syndrome
12%
Radiotherapy
11%
Lenalidomide
11%
Previously Untreated
11%
Ultra-low Dose
11%
Phase II Trial
11%
Overall Response Rate
10%
Treatment Strategy
10%
Etoposide
10%
Newly Diagnosed
10%
High Risk
10%
Positron Emission Tomography-computed Tomography (PET-CT)
9%
SUVmax
9%
Advanced Stage
9%
Anti-CD19 chimeric Antigen Receptor T Cells
8%
Clinical Trials
8%
Median Progression-free Survival
8%
Pharmacology, Toxicology and Pharmaceutical Science
Rituximab
54%
Diffuse Large B Cell Lymphoma
52%
Chimeric Antigen Receptor
49%
Large Cell Lymphoma
38%
Diseases
34%
Progression Free Survival
28%
Axicabtagene Ciloleucel
27%
Chemotherapy
27%
Overall Survival
25%
Cyclophosphamide
25%
B Cell Lymphoma
24%
Malignant Neoplasm
24%
Doxorubicin
21%
Vincristine
21%
Mantle Cell Lymphoma
20%
Follicular Lymphoma
19%
Cytokine Release Syndrome
17%
Prednisone
15%
Adverse Event
15%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
15%
Nonhodgkin Lymphoma
14%
Ibrutinib
14%
Lenalidomide
13%
Clinical Trial
12%
Event Free Survival
12%
Remission
9%
Dexamethasone
9%
Neoplasm
9%
Survival Rate
9%
Methotrexate
8%
Etoposide
8%
Disease Exacerbation
8%
Marginal Zone Lymphoma
8%
Venetoclax
7%
Toxicity and Intoxication
6%
Neutropenia
6%
Cytopenia
6%
Cytarabine
6%
Immunotherapy
5%
Classical Hodgkin Lymphoma
5%
Obinutuzumab
5%
Circulating Tumor DNA
5%
Mosunetuzumab
5%